## Alexander Liede

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5956632/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence and Risk Factors of Pneumonitis in Patients with Non-Small Cell Lung Cancer: An Observational Analysis of Real-World Data. Oncology and Therapy, 2021, 9, 471-488.	1.0	6
2	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer, 2020, 123, 268-274.	2.9	20
3	Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. Cancer Medicine, 2019, 8, 374-382.	1.3	6
4	Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data. Supportive Care in Cancer, 2018, 26, 2833-2841.	1.0	13
5	Treatment dynamics of boneâ€ŧargeting agents among men with bone metastases from prostate cancer in the United States. Pharmacoepidemiology and Drug Safety, 2018, 27, 229-238.	0.9	8
6	Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data. Supportive Care in Cancer, 2018, 26, 807-812.	1.0	4
7	Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Research and Treatment, 2018, 167, 517-528.	1.1	20
8	How well can familial hypercholesterolemia be identified in an electronic health record database?. Clinical Epidemiology, 2018, Volume 10, 1667-1677.	1.5	6
9	Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. Clinical Epidemiology, 2018, Volume 10, 1349-1358.	1.5	11
10	Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Research and Treatment, 2018, 171, 435-442.	1.1	73
11	Epidemiology of benign giant cell tumor of bone in the Chinese population. Journal of Bone Oncology, 2018, 12, 96-100.	1.0	18
12	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncolmmunology, 2018, 7, e1480301.	2.1	48
13	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Research and Treatment, 2017, 165, 433-444.	1.1	31
14	Prevalence of hypercalcemia of malignancy among pediatric cancer patients in the UK Clinical Practice Research Datalink database. Clinical Epidemiology, 2017, Volume 9, 339-343.	1.5	6
15	Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clinical Epidemiology, 2017, Volume 9, 267-277.	1.5	155
16	International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open, 2016, 1, e000040.	2.0	34
17	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Supportive Care in Cancer, 2016, 24, 3557-3565.	1.0	32
18	The incidence of bone metastasis after early-stage breast cancer in Canada. Breast Cancer Research and Treatment, 2016, 156, 587-595.	1.1	49

Alexander Liede

#	Article	IF	CITATIONS
19	Prevalence of hypercalcemia among cancer patients in the United States. Cancer Medicine, 2016, 5, 2091-2100.	1.3	75
20	Population-based study of giant cell tumor of bone in Sweden (1983–2011). Cancer Epidemiology, 2016, 42, 82-89.	0.8	40
21	Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data. Blood, 2016, 128, 2364-2364.	0.6	0
22	Validation of algorithms to detect distant metastases in men with prostate cancer using routine registry data in Denmark. Clinical Epidemiology, 2015, 7, 259.	1.5	5
23	Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States. Clinical Epidemiology, 2015, 7, 335.	1.5	47
24	Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction. Clinical Epidemiology, 2015, 7, 441.	1.5	29
25	Effect of Breast Cancer After Ovarian Cancer on Mortality forBRCAMutation Carriers. JAMA Surgery, 2015, 150, 490.	2.2	0
26	Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. Cancer Medicine, 2015, 4, 713-720.	1.3	9
27	Prevalence of hypercalcemia of malignancy among cancer patients in the UK: analysis of the Clinical Practice Research Datalink database. Cancer Epidemiology, 2015, 39, 901-907.	0.8	41
28	Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. Cancer Epidemiology, 2015, 39, 623-632.	0.8	10
29	Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data. Blood, 2015, 126, 4501-4501.	0.6	3
30	Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records. Canadian Journal of Urology, 2015, 22, 7858-64.	0.0	3
31	Bone Metastases, Skeletal-related Events, and Survival Among Children With Cancer in Denmark. Journal of Pediatric Hematology/Oncology, 2014, 36, 528-533.	0.3	9
32	Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States. Breast Cancer Research and Treatment, 2014, 146, 637-646.	1.1	1
33	Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Supportive Care in Cancer, 2014, 22, 2697-2705.	1.0	12
34	Prevalence of Patients With Nonmetastatic Prostate Cancer on Androgen Deprivation Therapy in the United States. Urology, 2013, 81, 1184-1189.	0.5	12
35	Frequency of the <i>CHEK2</i> 1100delC Mutation among Women with Breast Cancer: An International Study. Cancer Research, 2008, 68, 2154-2157.	0.4	54
36	Method of Cooking and Risk of Breast Cancer in the Philippines. Cancer Causes and Control, 2006, 17, 341-348.	0.8	5

ALEXANDER LIEDE

#	Article	IF	CITATIONS
37	BRCA mutations in Italian breast/ovarian cancer families. European Journal of Human Genetics, 2002, 10, 150-152.	1.4	178
38	Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan. American Journal of Human Genetics, 2002, 71, 595-606.	2.6	125
39	Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer. Journal of Clinical Oncology, 2002, 20, 1570-1577.	0.8	80
40	Hereditary breast and ovarian cancer in Asia: genetic epidemiology ofBRCA1 andBRCA2. Human Mutation, 2002, 20, 413-424.	1.1	123
41	BRCA1 andBRCA2 mutations among breast cancer patients from the Philippines. International Journal of Cancer, 2002, 98, 596-603.	2.3	83
42	A Method for Analyzing Videotaped Genetic Counseling Sessions. Journal of Genetic Counseling, 2000, 9, 117-136.	0.9	7
43	Evaluation of the Needs of Male Carriers of Mutations in BRCA1 or BRCA2 Who Have Undergone Genetic Counseling. American Journal of Human Genetics, 2000, 67, 1494-1504.	2.6	91
44	Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. Journal of the National Cancer Institute, 1999, 91, 1241-1247.	3.0	363
45	A Breast Cancer Patient of Scottish Descent with Germ-Line Mutations in BRCA1 and BRCA2. American Journal of Human Genetics, 1998, 62, 1543-1544.	2.6	30
46	A family with three germline mutations in <i>BRCAl</i> and <i>BRCA2</i> . Clinical Genetics, 1998, 54, 215-218.	1.0	13